AroCell (IDLDX.ST) Stock Analysis & AI Equity Report
AroCell (IDLDX.ST) overview
AroCell (IDLDX.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, AroCell reported revenue of SEK 57.4m and operating profit of SEK -43.4m; the year-end share price was 0.39 SEK and market capitalisation was SEK 89.8m. AroCell is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AroCell's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-08-30. Data will be refreshed during report generation.
About AroCell
AroCell AB (publ), now operating as IDL Diagnostics, develops, manufactures and sells in vitro diagnostic tests for cancer and bacterial infections. Its portfolio includes point-of-care, rapid and laboratory tests, including TK 210 ELISA for thymidine kinase 1 measurement and UBC Rapid and TUBEX TF, supported by in-house research, production and sales.
Generate the AroCell report
AroCell is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AroCell and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.